NutriBand Secures Amended Three-Year $5 Million Credit Line at 7% to Support AVERSA

NutriBand secured an amended three-year, $5 million credit line at 7% interest to fund the AVERSA fentanyl transdermal system through FDA approval and commercial manufacturing. This facility replaces a prior expiring agreement, enhancing liquidity for product development without allowing conversion to common stock.

NutriBand entered into an amended three-year $5.0 million credit line to support its AVERSA fentanyl transdermal system through FDA approval and into commercial-scale manufacturing. The facility bears interest at 7% per annum and does not allow conversion of outstanding amounts into common stock. The agreement replaces a prior $5.0 million facility that was scheduled to expire on July 13, 2026, enhancing liquidity for product development and launch.

Agreement details:

Agreement type: Amended three-year $5 million credit line facility at 7% interest
Signed / Effective: Jun 01 2026 / same
Duration / Termination: 3 years
Reason: Fund AVERSA through FDA approval and commercialization

Original SEC Filing: NutriBand Inc. [ NTRB ] - 8-K - Jun. 22, 2026

Disclaimer

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.